TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30798143
Drug: Fluency therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluency therapy only
Study: 25358227
Drug: Volar subcutaneous
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar subcutaneous digital block
Study: 25358227
Drug: Dorsal two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal two injections block
Study: 18600509
Drug: urate-lowering agents
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: urate-lowering agents
Study: 15980629
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 5 or 7-10 days
Study: 12054164
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (mean dose, 0.18 IU/kg per week)
Study: 7767551
Drug: Inhaled Atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Atrial Natriuretic Peptide (ANP)
Study: 7767551
Drug: Thiorphan (NEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (NEP inhibitor) alone
Study: 7767551
Drug: Inhaled Atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Atrial Natriuretic Peptide (ANP) with Thiorphan
Study: 2181102
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral zidovudine therapy (80, 120, or 160 mg/m2/dose, with oral dose being 1.5 times the intravenous dosage)
Study: 26359188
Drug: Intravitreal fluocinolone
Normalized name: Fluocinolone Acetonide Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal fluocinolone acetonide implant therapy
Study: 11896510
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of calcium antagonists
Study: 11896510
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with calcium antagonists
Study: 10573634
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation (Neoral)
Study: 10573634
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation (Sandimmune)
Study: 2620952
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg d-tubocurarine
Study: 2620952
Drug: 0.12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg pancuronium bromide
Study: 30725091
Drug: Trimetazidine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine, 20 mg, 3 times daily (n=27)
Study: 26267984
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib administered 1 hour before surgery
Study: 26267984
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before surgery
Study: 22717960
Drug: Polydextrose-containing smoothie
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose-containing smoothie (12 g, 3%)
Study: 16739544
Drug: RS treatment
Normalized name: PYRITHIONE ZINC 0.1 g in 100 mL TOPICAL LIQUID [Head and Shoulders Treatment Hair Thickening Step 2]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS treatment alone for two minutes
Study: 16739544
Drug: AL irradiation
Normalized name: AL-034
DrugBank: AL-034 (DB17471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL irradiation before RS treatment
Study: 12092185
Drug: Simvastatin (Zocor)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (Zocor) administered to 86% of cases at therapeutic doses for 6 months to one year
Study: 9444579
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment based on bedrest for a minimum of two weeks
Study: 9444579
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (no surgery)
Study: 2896636
Drug: levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: levocabastine nasal spray
Study: 26639849
Drug: Licorice flavonoid
Normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice flavonoid oil (LFO) 600 mg single dose
Study: 26639849
Drug: Licorice flavonoid
Normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice flavonoid oil (LFO) 300 mg repeated ingestion for 8 days
Study: 18971536
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg once daily for 24 weeks
Study: 10739171
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 and D3 receptor gene polymorphisms
Study: 9358666
Drug: 3-drug antitubercular
Normalized name: ANTITUBERCULARS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug antitubercular treatment (group A)
Study: 1480310
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (50 mg tablet, 3 times daily for 2 weeks)
Study: 1480310
Drug: Oxerutin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutin (1,500 mg tablet, 3 times daily for 2 weeks)
Study: 2951198
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 to 20 mg at night)
Study: 26991772
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg daily for 4 weeks
Study: 15839735
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (song)
Study: 8815088
Drug: Final sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final sensitivity after Chelex treatment of PCR-negative samples
Study: 31383985
Drug: Dose-dense early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC)
Study: 31383985
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy alone
Study: 26421292
Drug: 0.45 mg
Normalized name: urea 0.45 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg ramosetron
Study: 26421292
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg ramosetron
Study: 23340914
Drug: Educational sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational sessions with pharmaceutical representatives and counterdetailing sessions by a clinical pharmacist
Study: 17414930
Drug: Micronutrients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients with 18 mg of iron
Study: 15682799
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.2% ropivacaine with fentanyl (CEA)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 5 mg twice daily (preschool Caucasians)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 10 mg once daily (preschool Caucasians)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 10 mg once daily (Caucasian school children)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 20 mg once daily (Caucasian school children)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 2.5 mg once daily (Oriental preschool children)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 5 mg once daily (Oriental preschool children)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 10 mg once daily (Oriental school children)
Study: 10510139
Drug: Bambuterol hydrochloride
Normalized name: bambuterol hydrochloride
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol hydrochloride 20 mg once daily (Oriental school children)
Study: 7577283
Drug: Lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5 mg kg‐1 i.v.
Study: 1685458
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg per capsule, 2 capsules once daily for 3 days)
Study: 1685458
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules once daily for 3 days)
Study: 7139566
Drug: Adriamycin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (70 mg/m2)
Study: 7139566
Drug: Vincristine (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (1.4 mg/m2) and Adriamycin (50 mg/m2)
Study: 7139566
Drug: Cyclophosphamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (750 mg/m2)
Study: 7139566
Drug: Adriamycin combination
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin combination
Study: 31421858
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (including lithium)
Study: 28222546
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (CIMTm) - collective modality
Study: 28222546
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (CIMTm) - individual modality
Study: 22410289
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 × 2 mg
Study: 22410289
Drug: Valsartan 2
Normalized name: valsartan 26 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 2 × 160 mg
Study: 17239682
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mobilized peripheral blood stem cells (PBSCs) with G-CSF
Study: 17239682
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mobilized PBSCs with G-CSF
Study: 8179082
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g intravenous at induction of anesthesia)
Study: 15599747
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g intravenous at induction of anesthesia)
Study: 11954897
Drug: Buprenorphine TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine TDS (0.8, 1.2, and 1.6 mg)
Study: 9706921
Drug: Drinking group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking group (mandatory oral fluids, approximately 150 mL)
Study: 9706921
Drug: Nondrinking group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrinking group (no oral fluids)
Study: 8561443
Drug: Tildiem 60
Normalized name: Tildiem 60 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildiem 60 mg (240 mg total daily dose in three divided doses)
Study: 8561443
Drug: Bi-Tildiem 120
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-Tildiem 120 mg (two daily doses)
Study: 30170304
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (20 g/d for 12 weeks)
Study: 30170304
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (20 g/d for 12 weeks)
Study: 20679180
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg per day for 8 days)
Study: 20679180
Drug: Caffeine (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (adenosine receptor antagonist)
Study: 17227688
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine potency 58,000 plaque-forming units/dose
Study: 17227688
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine potency 207,000 plaque-forming units/dose
Study: 9201779
Drug: Caffeine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (500 mg)
Study: 10080053
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg loading dose)
Study: 7589767
Drug: Diltiazem 200-300
Normalized name: diltiazem hydrochloride 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 200-300 mg once daily
Study: 7589767
Drug: Captopril 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5-25 mg twice daily
Study: 25843821
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.25 μg/kg/minute (group 1)
Study: 25843821
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.75 μg/kg/minute (group 3)
Study: 25108752
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with exercise
Study: 19440896
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) control condition
Study: 17439512
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Study: 17439512
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (10 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Study: 17439512
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (20 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days)
Study: 17439512
Drug: Group 4
Normalized name: Chlamydophila psittaci biogroup 4 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 (20 mg rabeprazole + 750 mg amoxicillin + 400 mg clarithromycin twice daily for 7 days)
Study: 9459252
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% administered through a 25-gauge needle (lido-25)
Study: 9459252
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% mixed with sodium bicarbonate administered through a 25-gauge needle (lido-bicarb-25)
Study: 9459252
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% administered through a 30-gauge needle (lido-30)
Study: 9459252
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% mixed with sodium bicarbonate administered through a 30-gauge needle (lido-bicarb-30)
Study: 7887377
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab (IIb/IIIa platelet receptor antagonist)
Study: 883331
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (partial mastectomy plus axillary dissection plus postoperative radiotherapy)
Study: 30653423
Drug: Site-specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-specific therapy based on gene expression profiling
Study: 30653423
Drug: Empirical chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical chemotherapy with paclitaxel and carboplatin (PC)
Study: 30429461
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant fibroblast growth factor-2 (rFGF-2)
Study: 27161105
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 300 mg/d WS® 5570
Study: 27161105
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d paroxetine
Study: 19410035
Drug: Glyceryl nitrate
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceryl nitrate (GN) 15 mg/24 hours transdermal patch
Study: 19410035
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) identical-looking patch
Study: 17656180
Drug: CARRA/LNG gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARRA/LNG gel (0.75 mg levonorgestrel)
Study: 17656180
Drug: Carraguard (CARRA)
Normalized name: Carya illinoinensis pollen
DrugBank: Carya illinoinensis pollen (DB10380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard (CARRA) gel
Study: 7760989
Drug: Benzodiazepines (diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone)
Study: 7760989
Drug: 5-HT-3 antagonist
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT-3 antagonist (ondansetron)
Study: 2139523
Drug: tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tamoxifen (TAM) (20 mg/die) until progression
Study: 2139523
Drug: tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tamoxifen (TAM) (20 mg/die for 14 days) then medroxyprogesterone acetate (MPA) (1500 mg/die p.o. for 14 days)
Study: 6998390
Drug: Topical cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cephradine
Study: 6998390
Drug: Intravenous cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cephradine
Study: 6998390
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intravenous cephradine
Study: 26970480
Drug: VP shunt
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP shunt insertion plus dopamine oral therapy (group A)
Study: 25483667
Drug: ID 9
Normalized name: Myeloid 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID 9 μg intradermal vaccine
Study: 25483667
Drug: IM 15
Normalized name: trimethoprim 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM 15 μg intramuscular vaccine
Study: 18701020
Drug: Diabetes specific
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes specific formula (Diason low energy: 313.8 kJ/100 ml)
Study: 15806000
Drug: Intranasal R112
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal R112 (3 mg/nostril every 4 hours x 2)
Study: 15806000
Drug: Intranasal R112
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal R112
Study: 10382126
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg bid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Study: 10382126
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg tid for 2 weeks plus RBC, 400 mg bid for 4 weeks
Study: 8884146
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (600 mg/day of GLA)
Study: 6362471
Drug: Enteric-coated Conjuvac
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated Conjuvac Timothy tablets
Study: 6362471
Drug: Enteric-coated Whole
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated Whole Timothy pollen tablets
Study: 6362471
Drug: Enteric-coated placebo
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated placebo tablets
Study: 30971419
Drug: Telephone-delivered cognitive-behavioural
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive-behavioural therapy (TCBT)
Study: 30971419
Drug: Web-delivered cognitive-behavioural
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-delivered cognitive-behavioural therapy (WCBT)
Study: 29797592
Drug: Eccentric-based injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric-based injury prevention program (IPP) administered 1 day post-match (MD+1)
Study: 29797592
Drug: Eccentric-based injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric-based injury prevention program (IPP) administered 3 days post-match (MD+3)
Study: 19918047
Drug: alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 10 mg/day
Study: 15938591
Drug: Omeprazole pre-treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole pre-treatment for 3 days
Study: 15938591
Drug: Alginate tablets
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate tablets alone
Study: 11984383
Drug: Standard anti-emetic
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-emetic treatment
Study: 26046967
Drug: Low-dose rhIGF‐I/rhIGFBP‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rhIGF‐I/rhIGFBP‐3 (30 mg/d)
Study: 26046967
Drug: High-dose rhIGF‐I/rhIGFBP‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhIGF‐I/rhIGFBP‐3 (60 mg/d)
Study: 23446019
Drug: Balanced saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced saline solution
Study: 17129461
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline (200 mg/d) twice daily